WHO recognition of 'etaroleucel” (CELZ-101) builds on prior 'olastrocel” (CELZ-201) milestone, reinforcing platform ...
CNW/ - Aramis Biotechnologies Inc. ("Aramis"), a Canadian company pioneering and a global leader in plant‑based bioproduction ...
Women in STEM bring diverse perspectives that are especially valuable in rare disease research. These conditions are complex and require innovative thinking. Attention to detail, empathy, and ...
Stockholm, Sweden Tuesday, February 10, 2026, 14:00 Hrs [IST] ...
Chronic and highly burdensome, atopic dermatitis affects an estimated 223 million people worldwide, with onset commonly occurring in infancy and childhood. Rising awareness among parents, coupled with ...
A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns ...
The FDA underwent significant changes during the first year of the second Trump administration, directly affecting business ...
Health insurance CEO testimony on Capitol Hill followed a fam | Insurers testifying to Congress last month again promised ...
The investigational oral therapy KTX-1001, also known as gintemetostat, is catching interest as a potential treatment for a subgroup of patients with multiple myeloma, as an expert explained in a ...
Post-diagnosis risk assessment clarifies cancer etiology and germline contribution, shaping therapeutic planning, prevention ...
A new study led by the University of Miami Miller School of Medicine's Kirill Martemyanov, Ph.D., and international ...
The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe must meet exacting standards for dosage, purity, and sterility. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results